BACKGROUND: Clostridium difficile infection (CDI) is the major cause of hospital-acquired bacterial diarrhoea. The incidence of CDI has been increasing in Canada, the US and Europe and severe cases are becoming more common. METHODS: A retrospective cohort study investigating all patients with an episode of CDI present at the Vienna University Hospital between 01 January 2012 and 31 December 2012 was conducted. All microbiologically confirmed C. difficile toxin positive cases were included, ribotyped and analysed regarding their clinical course. RESULTS: A total of 278 patients with CDI were recorded, with an overall CDI incidence of 5.23 per 10,000 patients-days. Around 84,5 % (235/278) of CDI cases would have been classified as severe CDI according to European Society of Clinical Microbiology and Infectious Diseases (ESCMID) if all criteria were used. According to Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America (SHEA/IDSA) guidelines only 16.5 % (46/278) could be classified as severe; with a severe CDI incidence of 4.41 and 0.86 per 10,000 patient-days, respectively. Multivariate analysis showed only a co-morbidity index of ≥ 3 (p = 0.013) as independent risk factor for severe CDI. No link between ribotype 027 and severity or clustering was observed in our study population. CONCLUSIONS: Special attention in terms of restrictive antibiotic prescription should be given to patients having a Charlson co-morbidity ≥ 3 at the time of hospital admission. SHEA/IDSA guidelines were more accurate than ESCMID criteria in predicting severe CDI in our collective, of mostly severely ill patients, in a tertiary care hospital setting.
BACKGROUND:Clostridium difficileinfection (CDI) is the major cause of hospital-acquired bacterial diarrhoea. The incidence of CDI has been increasing in Canada, the US and Europe and severe cases are becoming more common. METHODS: A retrospective cohort study investigating all patients with an episode of CDI present at the Vienna University Hospital between 01 January 2012 and 31 December 2012 was conducted. All microbiologically confirmed C. difficile toxin positive cases were included, ribotyped and analysed regarding their clinical course. RESULTS: A total of 278 patients with CDI were recorded, with an overall CDI incidence of 5.23 per 10,000 patients-days. Around 84,5 % (235/278) of CDI cases would have been classified as severe CDI according to European Society of Clinical Microbiology and Infectious Diseases (ESCMID) if all criteria were used. According to Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America (SHEA/IDSA) guidelines only 16.5 % (46/278) could be classified as severe; with a severe CDI incidence of 4.41 and 0.86 per 10,000 patient-days, respectively. Multivariate analysis showed only a co-morbidity index of ≥ 3 (p = 0.013) as independent risk factor for severe CDI. No link between ribotype 027 and severity or clustering was observed in our study population. CONCLUSIONS: Special attention in terms of restrictive antibiotic prescription should be given to patients having a Charlson co-morbidity ≥ 3 at the time of hospital admission. SHEA/IDSA guidelines were more accurate than ESCMID criteria in predicting severe CDI in our collective, of mostly severely ill patients, in a tertiary care hospital setting.
Authors: J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch Journal: Eur J Clin Microbiol Infect Dis Date: 2011-12-31 Impact factor: 3.267
Authors: Seth T Walk; Dejan Micic; Ruchika Jain; Eugene S Lo; Itishree Trivedi; Eugene W Liu; Luay M Almassalha; Sarah A Ewing; Cathrin Ring; Andrzej T Galecki; Mary A M Rogers; Laraine Washer; Duane W Newton; Preeti N Malani; Vincent B Young; David M Aronoff Journal: Clin Infect Dis Date: 2012-09-12 Impact factor: 9.079
Authors: J M Wenisch; D Schmid; G Tucek; H-W Kuo; F Allerberger; V Michl; P Tesik; H Laferl; C Wenisch Journal: Infection Date: 2012-04-17 Impact factor: 3.553
Authors: D Schmid; H W Kuo; E Simons; E E Kanitz; J Wenisch; F Allerberger; C Wenisch Journal: J Infect Public Health Date: 2013-11-11 Impact factor: 3.718
Authors: T Inns; R Gorton; A Berrington; A Sails; T Lamagni; J Collins; J Perry; K Hill; J Magee; K Gould Journal: J Hosp Infect Date: 2013-06-10 Impact factor: 3.926
Authors: A Indra; S Huhulescu; M Schneeweis; P Hasenberger; S Kernbichler; A Fiedler; G Wewalka; F Allerberger; E J Kuijper Journal: J Med Microbiol Date: 2008-11 Impact factor: 2.472
Authors: Luigi Segagni Lusignani; Alexander Blacky; Peter Starzengruber; Magda Diab-Elschahawi; Thomas Wrba; Elisabeth Presterl Journal: Wien Klin Wochenschr Date: 2016-01-27 Impact factor: 1.704
Authors: Zsuzsanna Kurti; Barbara D Lovasz; Michael D Mandel; Zoltan Csima; Petra A Golovics; Bence D Csako; Anna Mohas; Lorant Gönczi; Krisztina B Gecse; Lajos S Kiss; Miklos Szathmari; Peter L Lakatos Journal: World J Gastroenterol Date: 2015-06-07 Impact factor: 5.742